News & Media / Newsroom
Alfasigma S.p.A today announced positive topline results from the OLINGUITO Phase 3 clinical trial (NCT05785611; Eudra CT 2022-501354-10-01),[i] evaluating filgotinib (marketed as Jyseleca® in approved indications) to treat adult patients with active axial spondyloarthritis (axSpA).
Alfasigma S.p.A (“Alfasigma” or the “Company”), a global pharmaceutical company founded over 75 years ago in Italy, where it is headquartered, today announced its financial results for the fiscal year 2024, reflecting a pivotal year of strategic transformation and significant growth.
Alfasigma is excited to announce that new findings from the multicenter-multicountry GALOCEAN (ph4) and SELECTION (ph3) studies, focusing on patients with moderate to severe Ulcerative Colitis, will be presented at the 20th Congress of the European Crohn’s and Colitis Organisation (ECCO) 2025.
Alfasigma today unveiled Morpho, the new brand identity of its Contract Development and Manufacturing Organization (CDMO) Business Unit. This announcement was made at CPHI 2024, the most important event in the pharmaceutical sector, specifically for Contract Development and Contract Manufacturing, taking place in Milan from October 8 to 10.
• Following a positive opinion from the EMA, the transfer of marketing authorization of Jyseleca from Galapagos NV to Alfasigma S.p.A has been approved by the European Commission.
• Alfasigma S.p.A. is responsible for providing filgotinib in Rheumatoid Arthritis and Ulcerative Colitis to patients in the European Union.
Alfasigma S.p.A has been selected as a finalist in the 20th edition of the M&A Awards: 20 Years of M&A in Italy, The Best Deals Of 2023, the initiative promoted by KPMG and Fineurop Soditic Spa, with the collaboration of Borsa Italiana and Class Editori, under the patronage of Bocconi University and AIFI, which rewards the best M&A transactions. The awards celebrate the importance of M&A as a strategic lever for business growth and competitiveness. Alfasigma has been shortlisted in the “Italian Acquisitions Abroad” category by a highly prestigious jury of industry experts, for the acquisition of Intercept Pharmaceuticals, Inc.
Corporate Communication & Institutional Relations
Staff
[email protected] +39.051.6489.511Press Office
[email protected]You’re entering Alfasigma global website
I agree